Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGF2PU)

• Drug Name: BNT411 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMGF2PU

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 7 (TLR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[3]
Hydroxychloroquine	DMSIVND	Chronic renal failure	GB61.Z	Approved	[4]
ANA773	DMSC8YW	Hepatitis C virus infection	1E51.1	Phase 2a	[5]
GS-9620	DMG5C8D	Hepatitis B virus infection	1E51.0	Phase 2	[6]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[7]
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[8]
LOXORIBINE	DMIV9ZE	Immune System disease	4A01-4B41	Phase 2	[9]
GSK2245035	DMBWPZJ	Asthma	CA23	Phase 2	[10]
AZD-8848	DM0M7QW	Allergic rhinitis	CA08.0	Phase 2	[11]
Isatoribine	DMHOJ8W	Hepatitis C virus infection	1E51.1	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT04101357) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of BioNTech.
• [3] Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
• [4] TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
• [5] Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
• [6] Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
• [7] Company report (Iderapharma)
• [8] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [9] The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
• [10] Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
• [11] Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
• [12] Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.